Antifungal susceptibility testing of filamentous fungi

Current Fungal Infection Reports

Volumn 6, Issue 1, 2012, Pages 41-50

  Espinel Ingroff, Ana ^a   Cantón, Emilia ^b   Pemán, Javier ^b  

^a Hospital Universitario y Politécnico la Fe ^*  (United States)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

AmphotericinB; Antifungal agents; Aspergillus; Caspofungin; Etest; Filamentous fungi; Microbial sensitivity tests; Mold; Neo Sensitabs; Susceptibility testing; Triazoles; YeastOne

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; ERGOSTEROL; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ANTIFUNGAL SUSCEPTIBILITY TEST; BROTH DILUTION; DERMATOPHYTE; DISK DIFFUSION; FUNGAL GENE; FUNGUS GROWTH; GENE MUTATION; HUMAN; HYALOHYPHOMYCOSIS; INCUBATION TIME; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; MOULD; NONHUMAN; POINT MUTATION; QUALITY CONTROL; REVIEW;

EID: 84862764706     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-011-0079-1     Document Type: Review

References (73)

1. Espinel-Ingroff A. In vitro susceptibility testing: when, where, and what to use. J Invasive Fungal Infect. 2008;2:52-61.
2. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: Biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47:1041-50.
3. Neofytos D, Horn D, Anaissie E, et al.: Epidemiology and outcome of invasive fungal infections in adult hematopoietic stem cell transplant recipients: analysis of multicenter PATH Alliance Registry. Clin Infect Dis. 2009;48:265-73.
4. Espinel-Ingroff A, Dawson K, Pfaller MA, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother. 1995;39:314-9.
5. Espinel-Ingroff A, Bartlett M, Chaturvedi V, et al. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. Antimicrob Agents Chemother. 2001;45:1828-35. (Pubitemid 32466356)
6. Espinel-Ingroff A, Fothergill A, Ghannoum M, et al. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M38-A document) of amphotericin B, itraconazole, posaconazole and voriconazole. J Clin Microbiol. 2005;43:5243-6. (Pubitemid 41484032)
7. Espinel-Ingroff A, Fothergill A, Ghannoum M, et al. Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidula-fungin against molds. J Clin Microbiol. 2007;45:2180-2. (Pubitemid 47203790)
8. Clinical and Laboratory Standards Institute: Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, 2nd ed. Document M38-A2. Clinical and Laboratory Standards Institute 2008.
9. Espinel-Ingroff A, Arthington-Skaggs B, et al. Muticenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B and caspofungin. Clin Microbiol. 2007;45:1811-20. (Pubitemid 46933912)
10. Espinel-Ingroff A, Canton, E, Fothergill, A, et al.: Quality control guidelines for amphotericin B, itraconazole, posaconazole and voriconazole disk diffusion susceptibility tests with non-supplemented Mueller-Hinton agar (M51-A document) for non-dermatophyte filamentous fungi. J Clin Microbiol. 2011;49:2568-71.
11. Clinical and Laboratory Standards Institute: Method for antifungal disk diffusion susceptibility testing of nondermatophyte filamentous fungi: Approved guideline. Document M51-A. Clinical and Laboratory Standards Institute, 2010.
12. Clinical and Laboratory Standards Institute: Performance standards for antifungal disk diffusion susceptibility testing of nondermatophyte filamentous fungi: Approved Informational Supplement. 2nd ed. Document M51-S2. Clinical and Laboratory Standards Institute, In preparation.
13. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect. 2008;14:982-4.
14. Espinel-Ingroff A. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev Iberoam Micol. 2008;25:99-104.
15. Araujo R, Espinel-Ingroff A. Antifungal resistance: cellular and molecular mechanisms. In: Ahmad I, editor. Combating Fungal Infections. Springer-Verlag, Heidelberg; 2010.
16. Blum G, Perkhofer S, Haas H, et al. Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob Agents Chemother. 2008;52:1553-5. (Pubitemid 351522034)
17. Seo K, Akiyoshi H, Ohnishi Y. Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus. Microbiol Immunol. 1999;43:1017-25.
18. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51:1897-904. (Pubitemid 46903071)
19. Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5:e219.
20. Krishnan-Natesan S, Chandrasekar PH, Alangaden GJ, Manavathu EK. Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demthylase A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus. Int J Antimicrob Agents. 2008;32:519-24.
21. Howard SJ, Cerar D, Anderson MJ, et al.: Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009;15:1068-76.
22. Mavridou E, Bruggemann RJ, Melchers WJ, et al.: Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother. 2010;54:860-5.
23. Chowdhary A, Kathuria S, Randhawa HS, et al. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother. 2011 Oct 25. (Epub ahead of print). A low incidence of azole resistance and gene mutations was reported in India.
24. Rocha EM, Garcia-Effron G, Park S, Perlin DS. A ser67Pro substitution in Fk51p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother. 2007;51:4174-6. (Pubitemid 350057823)
25. Katiyar SK, Edlind TD: Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 2009;53:1772-8.
26. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother. 2008;52:2468-72. (Pubitemid 351915677)
27. Pfaller MA, Diekema DJ, Ghannoum MA, et al.: Wild type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standard Institute broth microdilution methods. J Clin Microbiol. 2009;47:3142-6.
28. Espinel-Ingroff A, Diekema DJ, Fothergill A, et al.: Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2). J Clin Microbiol. 2010;48:3251-7.
29. Espinel-Ingroff A, Fothergill A, Fuller J, et al.: Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother. 2011;55:2855-9.
30. Espinel-Ingroff A, Cuenca-Estrella M, Fothergill et al.: Wild-Type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilu-tion method (M38-A2 document). Antimicrob Agents Chemother. 2011;55:5150-4.
31. Pfaller MA, Messer SA, Boyken L, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus spp. J Clin Microbiol. 2008;46:2568-72.
32. Almyroudis NG, Sutton DA, Fothergill AW, et al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother. 2007;51:2587-90. (Pubitemid 47047341)
33. Vitale RG, de Hoog GS, Schwarz P, et al.: Antifungal susceptibility and phylogeny of opportunistic members of Mucorales. J Clin Microbiol. 2011;Nov 9. doi:10.1128/JCM.06133-11.
34. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, et al.: Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother. 2009;53:4514-7.
35. Verweij, PE, Howard SJ, Melchers WJG, et al.: Azole resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat. 2009;12:141-7.
36. Lass-Florl C, et al.: In-vitro activities of various antifungal drugs against Aspergillus terreus: global assess using the methods of the European Committee on Antimicrobial Susceptibility testing. J Antimicrob Chemother. 2009;53:794-5.
37. Baddley JW, Marr KA, Andes DR, et al.: Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the transplant-associated infection survey network. J Clin Microbiol. 2009;47:3271-5.
38. van der Linden JW, Snelders E, Kampinga GA. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg Infect Dis. 2011;17:1846-54.
39. Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol. 2003;41:403-9. (Pubitemid 36098607)
40. Espinel-Ingroff A. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing Zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. J Clin Microbiol. 2006;44:3616-22. (Pubitemid 46768814)
41. Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother. 2008;61(3):616-20. (Pubitemid 351321136)
42. Dalhoff A, Ambrose PG, Mouton JW: A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection. 2009;37:296-305.
43. Turnidge J, Kahmeter G, Kronvall G Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect. 2006;12:418-25.
44. Walsh TJ, Raad I, Patterson T, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2-12. (Pubitemid 44968977)
45. Steinbach WJ, Perfect JR, Schell WA, et al. In vitro analysis, animal models, and 60 clinical cases of invasive Aspergillus ter-reus infection. Antimicrob Agents Chemother. 2004;38:3217-25. (Pubitemid 39129310)
46. Espinel-Ingroff A, Canton E, Peman J: Updates in antifungal susceptibility testing of filamentous fungi. Curr Fung Infect Rep. 2009;3:133-41.
47. Novicki TJ, LaFe K, Bui L, et al. Genetic diversity among clinical isolates of Acremonium strictum determined during an investigation of a fatal mycosis. J Clin Microbiol. 2003;41:2623-8. (Pubitemid 36712476)
48. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol. 2001;39:2431-8. (Pubitemid 32606215)
49. van der Linden JWM, Jansen RR, Bresters D, et al.: Azole resistant central nervous system aspergillosis. Clin Infect Dis. 2009;48:1111-3.
50. Verweij PE, Mellado E, Melchers WJ. Multiple triazole-resistance in aspergillosis. N Engl J Med. 2007;356:1481-3.
51. van den Brink HJ, Van Nistelrooy HJ, de Waard MA, et al. Increased resistance to 14-alpha demethylase inhibitors (DMIs) in Aspergillus niger by coexpression of the Penicillium italicum eburicol 4-alpha-demethylase (cyp51) and the A. niger cytochrome P-450 reductase (cypA). J Biotechnol. 1996;49:1318.
52. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2-12. (Pubitemid 44968977)
53. Castiglioni B, Sutton DA, Rinaldi MG, et al. Pseudallescheria boydii (anamorph Scedosporium apiospermum) infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine. 2002;81:333-48.
54. Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedo-sporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;2008(52):1743-50. (Pubitemid 351614668)
55. Rodriguez-Tudela JL, Hope W, Cuenca-Estrella M, et al.: Can we achieve clinical breakpoints for the triazoles in aspergillosis? Curr Fungal Infect Rep. 2011;5:128-34.
56. Sun QN, Najvar LK, Bocanegra R, et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002;46:2310-2. (Pubitemid 34665939)
57. Rodríguez MM, Pastor FJ, Sutton DA, et al. Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob Agents Chemother. 2010;54:1665-9.
58. Gardiner RE, Souteropoulos P, Park S, Perlin DS. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Mycoses. 2005;43:S299-305. (Pubitemid 41038582)
59. Walker LA, Gow NA, Munro CA: Fungal echinocandin resistance. Fungal Genet Biol. 2010;47:117-26.
60. Arendrup, MC, et al.: Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implications for susceptibility testing. Antimicrob Agents Chemother. 2009;53:1185-93.
61. Arendrup MC, Perkhofer S, Howard SJ, et al. Establishing in vitro-in vivo correlations of Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother. 2008;52:3504-11.
62. Madureira A, et al. Breakthrough invasive aspergillosis in allogeneic hematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents. 2007;30:551-4. (Pubitemid 350051779)
63. Castro C, Serrano MC, Florez B, et al. Comparison of sensititre YeastOne colorimetric antifungal panel with a modified NCCLS M38-A method to determine the activity of voriconazole against clinical isolates of Aspergillus spp. J Clin Microbiol. 2004;42:4358-60. (Pubitemid 39296177)
64. Linares MJ, Charriel G, Solis F, et al. Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods. J Clin Microbiol. 2005;43:250-3. (Pubitemid 40096308)
65. Martin-Mazuelos E, Peman J, Valverde A, et al. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J Antimicrob Chemother. 2003;52:365-70. (Pubitemid 37120713)
66. Torres-Narbona M, Guinea J, Martinez-Alarcon J, et al. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne and Etest. Antimicrob Agents Chemother. 2007;51:1126-9. (Pubitemid 46355313)
67. Alvarado-Ramirez E, Torres-Rodriguez JM. In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods. Antimicrob Agents Chemother. 2007;51:2420-3. (Pubitemid 47047319)
68. Espinel-Ingroff A, Canton E. Comparison of Neo-Sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for testing susceptibility of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole and voriconazole. J Clin Microbiol. 2008;46:1793-803. (Pubitemid 351657231)
69. Espinel-Ingroff A. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol. 2001;39:1360-7. (Pubitemid 32275436)
70. Espinel-Ingroff A, Rezusta A. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J Clin Microbiol. 2002;40:2101-7. (Pubitemid 34596392)
71. Pfaller JB, Messer SA, Hollis RJ, et al. In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs. J Clin Microbiol. 2003;41:1126-9. (Pubitemid 36307117)
72. Messer SA, Diekema DJ, Hollis RJ, et al. Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi. J Clin Microbiol. 2007;45:1322-4. (Pubitemid 46626507)
73. Garcia-Effron G, Dilger A, Alcazar-Fuoli L, et al. Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J Clin Microbiol. 2008;46:1200-6. (Pubitemid 351563556)